The promise of conjugate vaccines for Africa

Vaccine

Volumn 25, Issue SUPPL. 1, 2007, Pages

  Kieny, Marie Paule ^a   LaForce, F Marc ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b PATH   (France)

Author keywords

Haemophilus influenzae b; Meningitis; Neisseria meningitidis; Pneumonia; Streptococcus pneumoniae; Vaccine strategy

Indexed keywords

CONJUGATE VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE MENINGOCOCCAL GROUP A CONJUGATE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE MENINGOCOCCAL GROUP C CONJUGATE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG; VACCINE;

AFRICA; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BACTERIAL VIRULENCE; CONJUGATION; DRUG EFFICACY; DRUG SAFETY; HEALTH PROGRAM; HERD IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INCIDENCE; MENINGITIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; T LYMPHOCYTE; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION;

AFRICA; BACTERIAL VACCINES; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; MASS IMMUNIZATION; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; VACCINES, CONJUGATE; WORLD HEALTH ORGANIZATION;

EID: 34547608824     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.001     Document Type: Article

References (11)

1. Pichichero M.E. Meningococcal conjugate vaccines. Exp Opin Biol Ther 5 (2005) 1475-1489
2. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., and Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326 (2003) 365-366
3. Snape M.D., Kelly D.F., Green B., Moxon E.R., Borrow R., and Pollard A.J. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Ped Inf Dis J 24 (2005) 128-131
4. de Greeff S.C., de Melker H.E., Spanjaard L., Schouls L.M., and van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25 (2006) 79-80
5. Larrauri A., Cano R., Garcia M., and Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23 (2005) 4097-4100
6. Jodar L., LaForce F.M., Ceccarini C., Aguado T., and Granoff D.M. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361 (2003) 1902-1904
7. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 (2003) 1737-1746
8. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 (2005) 1139-1146
9. Trotter C.L., Gay N.J., and Edmunds W. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 162 (2005) 89-100
10. Henderson R.H. The Expanded Programme on Immunization of the World Health Organization. Rev Infect Dis 6 Suppl 2 (1984) S475-S479
11. Anonymous. Conclusions and recommendations from the Immunization Strategic Advisory Group. Wkly Epidemiol Rec 81 (2006) 2-11